盐酸缬更昔洛韦片疗效如何呢？

Valganciclovir hydrochloride tablets are the prodrug of ganciclovir. Valganciclovir hydrochloride tablets can be well absorbed from the gastrointestinal tract and rapidly metabolized into ganciclovir in the small intestinal wall and liver. The absolute bioavailability of ganciclovir converted from valganciclovir is approximately 60%. The systemic exposure of valganciclovir hydrochloride tablets is small and transient. The 24-hour area under the curve AUC24 and peak concentration (Cmax) are only 1% and 3% of ganciclovir respectively. The proportional relationship between the oral dose of valganciclovir hydrochloride tablets of 450-2625 mg and the AUC of ganciclovir was only studied under postprandial conditions. Valganciclovir Hydrochloride Tablets When the recommended dose of 900 mg of Valganciclovir Hydrochloride Tablets was taken with food, the mean AUC24 and Cmax measured with ganciclovir were increased by approximately 30% and approximately 14%, respectively. Therefore, it is recommended to take Valganciclovir Hydrochloride Tablets with food.

Valganciclovir Hydrochloride Tablets for the maintenance treatment of CMV retinitis: After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis.

What is the efficacy of Valganciclovir Hydrochloride Tablets?

Clinical studies of valganciclovir hydrochloride tablets in AIDS patients infected with CMV retinitis have shown that valganciclovir hydrochloride tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the valganciclovir hydrochloride tablet group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with valganciclovir hydrochloride tablets 900 mg per day. Among patients who received induction therapy with valganciclovir hydrochloride tablets or intravenous ganciclovir tablets followed by maintenance therapy, the mean (median) time from randomization to progression of CMV retinitis was: 226 (160) days and 219 (125) days.